Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformatio...( - Company Projects Seven Products to...),Health

- Company Projects Seven Products to Reach Sales of $1 Billion or More in

2008 - Late-Stage Pipeline Offers Promising Outlook; 6 Launches Expected by end

of 2011 - R&D Investment and Productivity Gains plus Aggressive Deal-Making Result

in Unprecedented 44 New Molecules Under Development - Transformation Efforts to Focus on Delivering Better Patient Outcomes - Lilly Reconfirms 2007 Sales and Earnings Guidance; Anticipates 2008 Sales Growth in the Mid-to-High Single Digits and Earnings of $3.85 to $4.00 Per Share; Compound Annual EPS Growth through 2011 Expected to be in Low Double

Digits.

NEW YORK, Dec. 6 /PRNewswire-FirstCall/ -- At its annual meeting with the investment community, Eli Lilly and Company (NYSE: LLY) today highlighted the progress on its expanding pipeline of innovative molecules and marketed products, provided investors with sales and earnings guidance for 2008, and reviewed the transformation efforts that the company is making to succeed in an increasingly challenging healthcare environment.

Transforming Lilly to Deliver Better Patient Outcomes

"We are changing our business model to provide a better value proposition to our customers," said Sidney Taurel, chairman and chief executive officer. "The Lilly we are evolving to will be a patient-centered enterprise that leverages the increasing role of tailored therapeutics. More specifically, we will focus our business on optimizing individual patient outcomes by providing patients with the right drug at the right dose at the right time. We are already seeing this concept put into action, most recently as we com
'/>"/>